The primary purpose of this study is to assess the safety and tolerability of AB598 in participants with advanced malignancies.
Phase 1 trials primarily test safety and dosing in a small number of participants (typically 20–100). Results do not yet speak to efficacy. FDA approval is typically many years away from this stage.
Enrollment is complete. The trial is in its follow-up or data collection phase — a readout may occur on or near the primary completion date.
Arcus Biosciences (ARQT) is the sponsoring company for this trial. BiotechSign currently grades this company F (31/100) based on composite catalyst signals across its full pipeline. This trial is one data point in that overall catalyst picture.